NASDAQ:ALGS

Aligos Therapeutics Stock Insider Trading

etoro logo Buy ALGS
*Your capital is at risk
$5.14
-0.110 (-2.10%)
At Close: Jun 03, 2026

Aligos Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.11M and sold 1.42M ALGS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 6.11M shares
Sell 1.42M shares
84% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Nuechterlein Carole
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Scopa James Paul
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Martell Bridget A
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Martell Bridget A
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Scopa James Paul
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Nuechterlein Carole
Director
Director 60 000
Value: $22.8K
Jun 27, 2024
Buy
Stock Option (Right to Buy)
A-Award
Hirth Peter
Director
Director 60 000
Value: $22.8K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Mcclure Matthew W.
Chief Medical Officer
Officer 72 000
Value: $81.4K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Calhoun Lesley Ann
See Remarks
Other 308 940
Value: $349.1K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Symons Julian A.
See Remarks
Officer 72 000
Value: $81.4K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Blatt Lawrence
Chief Executive Officer
CEO / President 965 435
Value: $1.09M
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Blatt Lawrence
Chief Executive Officer
CEO / President 965 435
Value: $1.09M
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Symons Julian A.
See Remarks
Officer 72 000
Value: $81.4K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Calhoun Lesley Ann
See Remarks
Other 308 940
Value: $349.1K
Mar 01, 2024
Buy
Stock Option (Right to Buy)
A-Award
Mcclure Matthew W.
Chief Medical Officer
Officer 72 000
Value: $81.4K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Hirth Peter
Director
Director 4 411
Value: $4K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Scopa James Paul
Director
Director 8 823
Value: $8K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Martell Bridget A
Director
Director 8 823
Value: $8K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Nuechterlein Carole
Director
Director 4 411
Value: $4K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Nielsen Jack
Director
Director 4 411
Value: $4K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Symons Julian A.
See Remarks
Officer 18 750
Value: $18.0K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Symons Julian A.
See Remarks
Officer 58 822
Value: $56.5K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Symons Julian A.
See Remarks
Officer 74 998
Value: $72.0K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Blatt Lawrence
Chief Executive Officer
CEO / President 57 749
Value: $55.4K
Feb 28, 2024
Buy
Stock Option (Right to Buy)
A-Award
Blatt Lawrence
Chief Executive Officer
CEO / President 132 352
Value: $127.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ALIGOS THERAPEUTICS INC.
Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The com...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE